RxDoctor Payments Data

Albert Lin, MD

Retina Specialist · Jackson, MSNPI 1669760385

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,966 of the $8,002 with a category attached, or 87.1%. AbbVie accounts for 96.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $5,874 and has fallen 98.3% since, to $100 in 2025.

$8,002in general payments, 2019–2025

Across 17 payments — averaging $470.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Cardinal Health 110 LLC$150
  • Genentech USA, Inc.$47
  • Astellas Pharma US Inc$29
  • Apellis Pharmaceuticals, Inc.$23
  • GSK$23
$167,971in research payments, 2019–2025

Across 9 payments — averaging $18,663 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$161K
  • AbbVie$7K

What the payments were for

  • Consulting fees$6,96687%
  • Travel & lodging$6458%
  • Food & beverage$3915%

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,254,690
Medicare patients
871
Services billed
18,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate138$7,854
CombiganBrimonidine Tartrate/Timolol17$4,722
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat150$2,926
Brimonidine Tartrate84$1,410
Ketorolac Tromethamine53$766
Latanoprost102$735
MethotrexateMethotrexate Sodium40$604
Atropine Sulfate17$552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan$7,729$4,72217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other retina specialist in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →